PE20110147A1 - Composicion y proceso - 356 - Google Patents

Composicion y proceso - 356

Info

Publication number
PE20110147A1
PE20110147A1 PE2010001171A PE2010001171A PE20110147A1 PE 20110147 A1 PE20110147 A1 PE 20110147A1 PE 2010001171 A PE2010001171 A PE 2010001171A PE 2010001171 A PE2010001171 A PE 2010001171A PE 20110147 A1 PE20110147 A1 PE 20110147A1
Authority
PE
Peru
Prior art keywords
pyrimidin
salt
metoxybenzyl
metoxifenil
methylmorpholin
Prior art date
Application number
PE2010001171A
Other languages
English (en)
Inventor
Helen Blade
Gwydion Huw Churchill
Angela Charlotte Currie
Benjamin Charles Dobson
Peter Samuel Hynes
Martin Neal Kenworthy
Lyn Powel
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20110147A1 publication Critical patent/PE20110147A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL Y SUS SALES FOSFATO, SULFATO, MALATO, ENTRE OTROS; QUE COMPRENDE: A) REACCION DE UNA SAL DE 5-[(2E)-3-(DIMETILAMINO)PROP-2-ENOIL]-2-METOXIBENCILO DEL ACIDO PIVALICO O ESTER METILICO CON UN URACILO SUSTITUIDO EN LA POSICION 6 PARA OBTENER UNA SAL DE 5- (2,4-DIOXO-1,2,3,4-TETRAHIDROPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; B) REACCION DEL OBTENIDO CON UN AGENTE HALOGENANTE PARA OBTENER UNA SAL DE 5-(2,4-DIHALOPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; C) HACER REACCIONAR EL OBTENIDO CON METILMORFOLINA; D) ELIMINAR LOS GRUPOS PROTECTORES PARA OBTENER EL COMPUESTO (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL. ADICIONALMENTE SE PUEDE AISLAR EL COMPUESTO EN MENCION COMO UNA SAL. TAMBIEN REFIERE A UNA FORMULACION FARMACEUTICA. DICHO PROCESO ES UTIL PARA PREPARAR COMPUESTOS INHIBIDORES DE LA QUINASA mTOR UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA COMO EL CANCER
PE2010001171A 2008-06-20 2009-06-18 Composicion y proceso - 356 PE20110147A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
PE20110147A1 true PE20110147A1 (es) 2011-03-26

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001171A PE20110147A1 (es) 2008-06-20 2009-06-18 Composicion y proceso - 356

Country Status (27)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
HK (1) HK1155160A1 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262504A1 (en) * 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
TW201500358A (zh) 2010-12-16 2015-01-01 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
FI3813946T3 (fi) 2018-06-15 2024-06-25 Janssen Pharmaceutica Nv Rapamysiinianalogeja ja niiden käyttötapoja
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
CA2382435C (en) 1999-09-07 2009-02-03 Syngenta Participations Ag Novel herbicidally active phenyl-substituted heterocycles
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7790709B2 (en) 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
JP2006525357A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー プロテインチロシンホスファターゼ阻害物質としての置換ヘテロアリール類
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
AU2006261607A1 (en) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
PL1954699T3 (pl) * 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
LT2057156T (lt) 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
MX2010004074A (es) 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.

Also Published As

Publication number Publication date
JP2011524889A (ja) 2011-09-08
DOP2010000391A (es) 2011-01-15
TWI441821B (zh) 2014-06-21
CR11859A (es) 2011-02-25
KR20110027789A (ko) 2011-03-16
AU2009261688B2 (en) 2012-07-05
US20090318434A1 (en) 2009-12-24
NI201000225A (es) 2011-12-15
TW201012818A (en) 2010-04-01
BRPI0914912A2 (pt) 2017-06-20
ZA201101861B (en) 2011-11-30
ECSP10010696A (es) 2011-01-31
CA2728183C (en) 2016-10-25
JP5607614B2 (ja) 2014-10-15
CL2010001488A1 (es) 2011-07-15
US8198441B2 (en) 2012-06-12
IL210074A0 (en) 2011-02-28
IL210074A (en) 2015-07-30
MX2010014230A (es) 2011-03-29
MY172107A (en) 2019-11-14
AR072263A1 (es) 2010-08-18
EA019092B1 (ru) 2014-01-30
HK1155160A1 (en) 2012-05-11
WO2009153597A2 (en) 2009-12-23
CN102137860B (zh) 2013-08-28
ES2398423T3 (es) 2013-03-19
KR101668497B1 (ko) 2016-10-21
WO2009153597A3 (en) 2010-05-06
EA201100063A1 (ru) 2011-10-31
CN102137860A (zh) 2011-07-27
CA2728183A1 (en) 2009-12-23
EP2303875B1 (en) 2012-11-28
EP2303875A2 (en) 2011-04-06
SV2010003770A (es) 2011-05-20
CO6351729A2 (es) 2011-12-20
AU2009261688A1 (en) 2009-12-23
UY31917A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
PE20110147A1 (es) Composicion y proceso - 356
AU2014272774B2 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
IL278766B2 (en) Molecule, N-(3-chloro-1-(pyridin-3-yl)-H1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide, for use in pest control
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
PE20100267A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
AR056786A1 (es) Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
GB0607954D0 (en) Organic compounds
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
BR122012012032B1 (pt) usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas
EA201100969A1 (ru) Солевые формы органического соединения
NZ590179A (en) Fatty acid acetylated salicylates, diflunisal or triflusal and their uses
PE20130386A1 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
MA37405A1 (fr) Composés hétérocyclyle
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
BR112014030577B1 (pt) Dihidronaftiridinas e compostos relacionados, bem como composições farmacêuticas compreendendo os mesmos
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
CL2008003181A1 (es) Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal